T Cell Development and T Cell Responses in Mice with Mutations Affecting Tyrosines 292 or 315 of the Zap-70 Protein Tyrosine Kinase by Magnan, Antoine et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/08/491/15 $5.00
Volume 194, Number 4, August 20, 2001 491–505
http://www.jem.org/cgi/content/full/194/4/491
 
491
 
T Cell Development and T Cell Responses in Mice with 
Mutations Affecting Tyrosines 292 or 315 of the ZAP-70 
Protein Tyrosine Kinase
 
Antoine Magnan,
 
1 
 
Vincenzo Di Bartolo,
 
2
 
 Anne-Marie Mura,
 
1
 
Claude Boyer,
 
1
 
 Mireille Richelme,
 
1
 
 Yea-Lih Lin,
 
1
 
 Agnès Roure,
 
1
 
Anne Gillet,
 
1
 
 Cécile Arrieumerlou,
 
3
 
 Oreste Acuto,
 
2
 
 Bernard Malissen,
 
1
 
and Marie Malissen
 
1
 
1
 
Centre d’Immunologie de Marseille-Luminy, Institut National de la Santé et de la Recherche 
Médicale (INSERM)-Centre National de la Recherche Scientiﬁque (CNRS)-Univ.Med., Parc 
Scientiﬁque de Luminy, 13288 Marseille Cedex 9, France
 
2
 
Molecular Immunology Unit, Institut Pasteur, 75724 Paris Cedex 15, France
 
3
 
Laboratoire d’Immuno-Pharmacologie, CNRS UPR 415, Institute Cochin de Génètique 
Moléculaire, 75014 Paris, France
 
Abstract
 
After stimulation of the T cell receptor (TCR), the tyrosine residues 292 and 315 in interdo-
main B of the protein tyrosine kinase ZAP-70 become phosphorylated and plausibly function
as docking sites for Cbl and Vav1, respectively. The two latter proteins have been suggested to
serve as substrates for ZAP-70 and to fine-tune its function. To address the role of these resi-
dues in T cell development and in the function of primary T cells, we have generated mice that
express ZAP-70 molecules with Tyr to Phe substitution at position 292 (Y292F) or 315
(Y315F). When analyzed in a sensitized TCR transgenic background, the ZAP-70 Y315F mu-
tation reduced the rate of positive selection and delayed the occurrence of negative selection.
Furthermore, this mutation unexpectedly affected the constitutive levels of the CD3-
 
 
 
 p21
phosphoisoform. Conversely, the ZAP-70 Y292F mutation upregulated proximal events in
TCR signaling and allowed more T cells to produce interleukin 2 and interferon 
 
 
 
 in response
to a given dose of antigen. The observation that ZAP-70 Y292F T cells have a slower rate of
ligand-induced TCR downmodulation suggests that Y292 is likely involved in regulating the
duration activated TCR reside at the cell surface. Furthermore, we showed that Y292 and
Y315 are dispensable for the TCR-induced tyrosine phosphorylation of Cbl and Vav1, respec-
tively. Therefore, other molecules present in the TCR signaling cassette act as additional adap-
tors for Cbl and Vav1. The present in vivo analyses extend previous data based on transformed
T cell lines and suggest that residue Y292 plays a role in attenuation of TCR signaling, whereas
residue Y315 enhances ZAP-70 function.
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Introduction
 
The CD3 subunits of the TCR contain conserved cytoplas-
mic sequences termed the immunoreceptor tyrosine-based
 
activation motifs (ITAMs).
 
*
 
 To exert their signaling func-
tions, ITAMs cooperate in a sequential manner with nonre-
ceptor protein tyrosine kinases (PTKs) belonging to the Src
and to the Syk/ZAP-70 PTK families (for a review, see ref-
erence 1). Two members of the Src family (Lck and to a
lesser degree Fyn) initiate T cell activation by phosphorylat-
ing the tyrosine residues located within each CD3 ITAM
and permitting the recruitment of ZAP-70 to the vicinity of
the activated TCR. Next, by phosphorylating a tyrosine
residue (Y493) located in the activation loop of the ZAP-70
catalytic domain, Lck increases the intrinsic kinase activity
of the ITAM-bound ZAP-70 molecules, which in turn
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*
 
Abbreviations used in this paper: 
 
DN, double negative; DP, double posi-
tive; ES, embryonic stem; ITAM, immunoreceptor tyrosine-based activa-
tion motif; PLC, phospholipase C; PTK, protein tyrosine kinase; SH, src
homology; SP, single positive. 
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phosphorylate the adaptors LAT and SLP-76 and possibly
other signaling proteins including Vav1, Cbl, and phospho-
lipase C (PLC)
 
 
 
-1. Therefore, ZAP-70 does constitute a
key player in the TCR signaling cassette and its ablation
blocks mouse intrathymic T cell development at the double
positive (DP) to single positive (SP) transition (2, 3).
Like Syk, ZAP-70 is composed of two tandemly ar-
ranged src homology (SH)2 domains which mediate its
association with phosphorylated ITAMs and of a COOH-
terminal tyrosine kinase domain. A linker region (interdo-
main B) located between the SH2 domains and the kinase
domain, contains three tyrosine residues at position 292,
315, and 319. After TCR stimulation, each of these resi-
dues is phosphorylated (4, 5). Studies of recombinant ZAP-
70 molecules in which tyrosines 292, 315, and 319 were
mutated to phenylalanine, indicated that these residues are
not directly involved in the regulation of ZAP-70 catalytic
activity (6), but rather act in trans by specifically recruiting
SH2 domain–containing molecules that regulate ZAP-70
activity and/or serve as substrate for ZAP-70. For instance,
ZAP-70 molecules with a Tyr 319 to Phe mutation (ZAP-
70 Y319F) fail to couple TCR ligation to downstream sig-
naling pathways in both Jurkat T cells and a ZAP-70–defi-
cient Jurkat derivative (7, 8). These observations correlate
with the inability of the ZAP-70 Y319F molecules to re-
cruit Lck and to upregulate their catalytic activity after
TCR cross-linking (9). Once phosphorylated, Tyr 315
may also contribute to TCR-induced signaling by serving
as an inducible binding site for the SH2 domain of Vav1, a
Rho family GDP/GTP exchange factor. However, analysis
of the functional consequence of the ZAP-70 Y315F mu-
tation has led to conflicting data, that may reflect variations
in the recipient cell lines used for gene transfer (7, 8, 10,
11). When expressed in Jurkat T cells, a ZAP-70 Y292F
mutant resulted in the constitutive expression of a NF-AT–
driven reporter gene (12, 13). Therefore, in contrast to
Y315 and Y319, Y292 appears to exert a negative regula-
tory effect on ZAP-70. The atypical SH2 domain found in
the adaptor Cbl binds to activated ZAP-70 via a motif that
involves phosphotyrosine 292, and to interdomain B of Syk
via an orthologous docking site (14, 15). Prevention of the
phosphotyrosine-dependent interaction between Cbl and
ZAP-70/Syk PTKs showed that Cbl is likely to be the pro-
tein that attenuates signaling by activated ZAP-70 and Syk
kinases (16–20). When expressed into ZAP-70–deficient
Jurkat T cells, ZAP-70 mutant molecules that lack most of
interdomain B showed a reduced kinase activity but were
still capable of reconstituting the TCR-driven induction of
multiple reporter genes (21). This paradoxical result may be
accounted for by the fact that this deletion simultaneously
removed one negative regulatory site (Y292) and two posi-
tive regulatory sites (Y315 and Y319), and resulted in a
compound phenotype. The above experiments, aiming at
assessing the biological activity of mutant ZAP-70 mole-
cules that fail to interact with defined cytoplasmic effec-
tors/adaptors, have mainly been performed with trans-
formed lymphoid cell lines in which some regulatory
pathways are profoundly disturbed (22). To define in vivo
the role of the tyrosines found in the ZAP-70 interdomain
B, we have generated knockin mice that express ZAP-70
molecules with a point mutation at position Y292 or Y315,
and determined their effects on T cell development and on
the function of ex vivo T cells challenged with physiologic
amounts of antigen.
 
Materials and Methods
 
Mice
 
The P14 (line 327, reference 23) and H-Y (24, 25) 
 
  
 
 TCR
transgenic lines were maintained on a C57BL/6 background.
CD3
 
 
 
–deficient mice were as described previously (CD3
 
 
 
 
 
5/
 
 
 
5
 
,
reference 26).
 
Vector Construction
 
ZAP-70 genomic clones were isolated from a 129/Ola phage
library. After establishing the partial exon–intron structure of the
ZAP-70 gene, the nucleotide sequence coding for interdomain B
was determined and the tyrosine residue found at position 292
and 315 separately mutated to phenylalanine as described below.
 
ZAP-70 Y292F Mutation
 
Mutagenesis was performed on a 170-bp Hinc II fragment en-
compassing exon 6. The mutated fragment was exchanged for the
wild-type Hinc II fragment contained in a 2.1-kb Bam HI-Sma I
restriction fragment subclone, and a diagnostic Cla I site and a
loxP-flanked neo
 
r
 
 gene introduced in the intron 3
 
 
 
 of exon 6. Fi-
nally, the targeting construct was extended to give 3.5 kb and 3.0
kb of homologous sequences 5
 
 
 
 and 3
 
  
 
of the neo
 
r
 
 gene, respec-
tively (see Fig. 1 A). After electroporation of E14 129/Ola em-
bryonic stem (ES) cells and selection in G418, colonies were
screened for homologous recombination by Southern blot analy-
sis using 5
 
 
 
 and 3
 
 
 
 single-copy probes. The 5
 
 
 
 probe is a 329-bp
Sac II-Sma I fragment isolated from a ZAP-70 cDNA and the 3
 
 
 
probe is a 1.1-kb KpnI-EcoRI fragment isolated from a ZAP-70
genomic clone. When tested on Xba I–digested DNA, the 3
 
 
 
probe hybridizes either to a 7.0-kb wild-type fragment or to a
6.2-kb recombinant fragment. On Eco RI–digested DNA, the 5
 
 
 
probe hybridizes either to a 13.5-kb wild-type fragment or to a
10.6-kb recombinant fragment. Homologous recombinant ES
clones were further checked for the presence of the intended mu-
tation by sequencing the genomic segment corresponding to
exon 6. Finally, a neo probe was used to ensure that adventitious
nonhomologous recombination events had not occurred in the
selected clones.
 
ZAP-70 Y315F Mutation
 
Mutagenesis was performed on a 220-bp Sma I-SphI fragment
containing the relevant segment of exon 7. A diagnostic Sac I re-
striction enzyme cleavage site was introduced into exon 7 to fa-
cilitate the subsequent identification of the ZAP-70 Y315F
mutant mice. This modification does not modify the resulting
ZAP-70 amino acid sequence with the exception of the Y315F
mutation. A loxP-flanked neo
 
r
 
 gene was additionally introduced
in the intron 5
 
 
 
 to exon 3. The final targeting construct contained
1.6 kb and 5 kb of homologous sequences 5
 
 
 
and 3
 
 
 
 of the neo
 
r
 
gene, respectively (Fig. 1 B). After electroporation and selection
in G418, recombinant colonies were identified by Southern blot 
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analysis using probes identical to those used for screening the
ZAP-70 Y292F recombinant colonies (see above). In the case of
the ZAP-70 Y315F mutation, the 3
 
 
 
 probe hybridizes either to a
7.0-kb wild-type fragment or to a 8.0-kb recombinant fragment,
whereas the 5
 
 
 
 probe hybridizes either to a 13.5-kb wild-type
fragment or to a 8.6-kb recombinant fragment. Homologous re-
combinant clones were confirmed via XbaI-SacI double digest
and determination of the genomic sequence corresponding to
exon 7. A neo probe was used to ensure that adventitious recom-
bination events had not occurred in the selected clone.
 
Production of Mutant Mice
 
Mutant ES cells were injected into Balb/c blastocysts. One
ZAP-70 Y292F and one ZAP-70 Y315F recombinant ES clones
were found capable of germline transmission. The neo
 
r
 
 gene
flanking the ZAP-70 Y292F and ZAP-70 Y315F mutant loci was
removed by crossing the chimeric mice to the Deleter mice (27).
Mice with deletion of the loxP-flanked neo
 
r
 
 gene were inter-
crossed to produce homozygous mutant mice. Screening of mice
for the presence of the intended ZAP-70 mutations was per-
formed by PCR using the following pairs of oligonucleotides:
Y292F a: 5
 
 
 
-ATGGAGGAGATGGCCATGCAGGGA-3
 
 
 
, and
Y292F b: 5
 
 
 
-GCATGGACAGACCCCTGGC-3
 
 
 
; Y315F c: 5
 
 
 
-
TGGGGAAAGCCACTGCTGGATGTC-3
 
 
 
, and Y315F d: 5
 
 
 
-
TGTGTGCTGGATGTAGGACCCAGG-3
 
 
 
. Most of the stud-
ies were performed after backcrossing the mutant mice on a
C57BL/6 background for at least five generations.
 
Flow Cytometric Analysis
 
Flow cytometric analysis was performed as described previ-
ously (28). Antibodies against CD3
 
 
 
 (2C11), CD4 (GK1.5),
CD8-
 
 
 
 (56-6.7), V
 
 
 
2 (B20.1), CD25 (7D4), CD69 (H1.2F3),
and CD5 (53-7.5) were purchased from BD PharMingen. The
biotinylated T3.70 anticlonotypic antibody (25) was a gift of
H.T. He and A.M. Bernard, Centre d’Immunologie de
Marseille-Luminy, Marseilles, France.
 
Antibodies
 
The following antibodies were used for immunoprecipitations
and Western blot analysis: anti-CD3 
 
 
 
 chain antiserum 873
(raised against a peptide corresponding to residues 1–11 of the
human 
 
 
 
 protein; 29), anti–ZAP-70 antiserum 50 (a gift of Dr.
J.-M. Rojo, Centro de Investigaciones Biologicas, CSIC, Madrid,
Spain), anti-Cbl (C-15) antiserum (purchased from Santa Cruz
Biotechnology, Inc.), anti–SLP-76 (a gift from Dr. G. Koretzky,
University of Pennsylvania, Philadelphia, PA), anti-Vav1, and
anti-LAT antisera were purchased from Upstate Biotechnology.
The anti-Vav1 monoclonal antibody Vav-30 was a gift of Dr. J.
Griffin (Dana Farber Cancer Institute, Boston, MA), the anti–
ZAP-70 monoclonal antibody clone 29 was purchased from
Transduction Laboratories, and the anti–PLC
 
 
 
-1 and the 4G10
antiphosphotyrosine monoclonal antibodies purchased from Up-
state Biotechnology.
 
Immunoprecipitation, SDS-PAGE, and Immunoblotting
 
Thymocytes or lymph node cells were incubated for 20 min on
ice with 20 
 
 
 
g/ml anti-CD3 Ab (2C11), and the bound antibod-
ies subsequently cross-linked with 20 
 
 
 
g/ml of goat anti–hamster
IgG for 3 min at 37
 
 
 
C. Cells were then lysed with 1% NP40-con-
taining lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-
40, 1 mM magnesium chloride, 1 mM EGTA, 50 mM sodium
fluoride, 10 mM sodium pyrophosphate, 10 
 
 
 
g/ml leupeptin, 10
 
 
 
g/ml aprotinin, 1 mM Pefabloc-SC, and 50 mM sodium ortho-
vanadate). Immunoprecipitation, immunoblotting, and detection
of proteins by enhanced chemiluminescence (Amersham Pharma-
cia Biotech) were performed as described previously (30).
 
Purification of CD8
 
 
 
 T Cells from Lymph Nodes
 
Lymph node cells were incubated with a cocktail of antibod-
ies directed against CD4 (H129.19.6), B220 (RA.36.B2), and
MHC class II (M5/114) molecules. Cells reacting with at least
one of the above antibodies were removed with Dynabeads
M450 precoated with sheep anti–rat IgG. Purity of the remain-
ing cells was controlled by flow cytometry. In all instances, this
purification protocol resulted in cell suspensions containing 96–
98% CD8
 
 
 
 T cells.
 
Intracellular Staining
 
Cytokines.
 
CD8
 
 
 
 T cells (0.5 
 
 
 
 10
 
6
 
) purified from lymph
nodes from P14 TCR transgenic mice were cultured in 24-well
plates in the presence of CD3
 
 
 
–deficient spleen cells (3 
 
  
 
10
 
6
 
)
that were prepulsed for 2 h with the p33 agonist peptide (10
 
 
 
8
 
M). After 0, 4, 19, 39, and 63 h, cells were collected, and
counted. Before intracellular cytokine staining, cells (1.5 
 
 
 
 10
 
6
 
)
were cultured for 4 h in the presence of monensin (GolgiStop;
BD PharMingen) at a final concentration of 2 
 
 
 
M. For staining,
cells were immediately placed on ice, washed, resuspended in
PBS 1
 
 
 
, 1% FCS, 0.09% sodium azide, and stained with an
APC-conjugated anti-CD8 antibody. To monitor intracellular
cytokines, cells were then fixed using the cytofix/cytoperm kit
(BD PharMingen), according to the manufacturer’s instructions.
Each cell sample was subsequently splitted into two aliquots; one
of them was stained with a combination of FITC-conjugated
anti–IFN-
 
 
 
 and PE-conjugated anti–IL-2 antibodies, and the
other stained with a combination of fluorochrome-conjugated
and isotype-matched negative control Ig (BD PharMingen). Af-
ter a final wash, CD8
 
 
 
 cells (10
 
4
 
) were analyzed on a FACSCali-
bur™ flow cytometer after gating out dead cells using forward
and side scatters.
 
Syk.
 
Cells were stained for the presence of Syk using the
5F5.2 anti-Syk monoclonal antibody (31).
 
TCR Downregulation and Induction of Cell-Surface Molecules
 
Lymph node T cells were cultured with peptide-loaded
RMA-S cells (32). After incubation at 37
 
 
 
C for the specified
time, cells were resuspended vigorously in PBS containing 0.5
mM EDTA and stained with antibody combinations allowing to
gate on CD8
 
 
 
 T cells and to simultaneously determine the levels
of V
 
 
 
2, CD3-
 
 
 
, CD25, or CD69. The extent of TCR downreg-
ulation on CD8
 
 
 
 T cells was normalized using the formula: per-
centage of TCR downregulation 
 
  
 
100 
 
 
 
 ([TCR mean fluores-
cence intensity in response to a RMA-S loaded with a given
peptide concentration/TCR mean fluorescence intensity in re-
sponse to RMA-S loaded with the same concentration of the
negative control AV peptide] 
 
 
 
 100).
 
Results
 
Generation of Mice with Mutations in Interdomain B of ZAP-
70.
 
Mice with Tyr to Phe mutation at position 292 or
315 of ZAP-70 were generated using the knockin strategy
outlined in Fig. 1. As compared with the reconstitution of
ZAP-70–deficient mice with transgenes encoding mutant 
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ZAP-70 molecules, the approach we selected readily per-
mits the expression of ZAP-70 mutant molecules at physi-
ological levels and with appropriate kinetics. To induce the
deletion of the loxP-flanked neomycin cassette, heterozy-
gous mice carrying either of the mutated ZAP-70 alleles
were crossed to the Deleter strain (27). The resulting prog-
eny was backcrossed on a C57BL/6 background and used
in further experiments. For the sake of comparison and
owing to the high degree of sequence conservation existing
between the mouse and human ZAP-70 interdomains B,
the tyrosine numbering originally proposed for human
ZAP-70 has been conserved for mouse ZAP-70. To con-
firm that the intended point mutations had been genuinely
introduced, ZAP-70 transcripts were cloned by reverse
transcription and PCR amplification from the thymus of
the mutated mice, and the presence of the Y292F or
Y315F mutations confirmed by DNA sequence analysis
(data not shown).
Mice deficient in Syk showed no major abnormalities in
 
  
 
 T cell development, whereas in mice deficient in ZAP-
70, thymocytes are arrested at the DP stage. Thymocytes
lacking both Syk and ZAP-70 are completely blocked at
the transition from the double negative (DN) stage. These
genetic studies indicate that Syk and ZAP-70 exert redun-
dant functions only during pre-TCR function, and are
consistent with the observation that Syk is quickly down-
regulated after the pre-TCR checkpoint (31). Taken to-
gether, these data suggest that any phenotypic effect associ-
ated with the ZAP-70 Y292F or ZAP-70 Y315F mutation
might become manifest only at or following the DP to SP
transition. Analysis of the thymus and secondary lymphoid
organs of ZAP-70 Y292F and ZAP-70 Y315F mice re-
vealed both a normal cellularity and a normal representa-
tion of T lymphocytes expressing surface levels of TCR
 
  
 
, CD3, CD4, CD8, CD69, CD44, and CD25 compara-
ble to those found in wild-type littermates (data not
shown). The absence of abnormal phenotype in the ZAP-
70 Y292F and ZAP-70 Y315F mice may result from adap-
tive mechanisms that have been set in motion to buffer the
effect of the ZAP-70 mutations. When placed under the
control of the proximal Lck promoter to reach a high level
of expression up to the SP stage, a Syk transgene was found
capable of restoring the DP to SP transition of ZAP-70–
deficient thymocytes (33). Therefore, in the ZAP-70
Figure 1. Generation and
identification of ZAP-70 Y292F
and ZAP-70 Y315F mice.
ZAP-70 Y292F mice. (A, 1).
Partial restriction endonuclease
map of the wild-type ZAP-70
gene. Exons 1–7 are shown as
black boxes. The restriction sites
are: R, Eco RI; and X, XbaI.
(A, 2) Targeting vector used for
introduction of the ZAP-70
Y292F mutation. The codon
present in exon 6 and corre-
sponding to residue Y292 was
mutated to phenylalanine. A di-
agnostic ClaI restriction site (C)
was simultaneously introduced
in the intron 3  of exon 6 to tag
the ZAP-70 Y292F mutation.
The targeting construct includes
a loxP-flanked neor gene in the
intron 3  of exon 6. LoxP sites
are shown as filled triangles and
the neor gene as a dotted box.
(A, 3) Structure of the targeted
locus. (A, 4) Final structure of the targeted locus after removal of the neor gene by Cre-mediated recombination. The 5  and 3  probes used to verify
the targeting events are indicated as black boxes and the position of the PCR primers (a and b) used to monitor the transmission of the mutant ZAP-70
Y292F allele indicated by triangles. (B) Southern blot analyses of recombinant ES cell clones before deletion of the neor gene. DNA from parental E14
cells and from a clone (292.F5) that gave germline transmission of the modified ZAP-70 allele were digested with XbaI and hybridized with the 3  sin-
gle-copy probe depicted in A. (C) DNA-PCR analysis of wild-type (w/w), heterozygous (w/m), and homozygous (m/m) littermates using the pair of
primers shown in A. The single Lox P site remaining in the modified ZAP-70 allele after deletion of the neor gene resulted in an amplified PCR prod-
uct 140 bp-longer than the one amplified from the wild-type allele. The amplified products were run on an agarose gel and stained with ethidium bro-
mide. ZAP-70 Y315F mice. (D, 1) Partial restriction map of the ZAP-70 gene. The restriction sites are: R, Eco RI; S, Sac I; and X, Xba I. (D, 2)
Targeting vector used for introduction of the ZAP-70 Y315F mutation. The codon present in exon 7 and corresponding to residue Y315 was mutated
to phenylalanine. A diagnostic Sac I site was simultaneously introduced in exon 7 to tag the ZAP-70 Y315F mutation. The targeting construct in-
cludes a loxP-flanked neor gene in the intron 5  to exon 3. (D, 3) Structure of the targeted locus. (D, 4) Structure of the targeted locus after removal
of the neor gene by Cre-mediated recombination. The 5  and 3  probes used for Southern blot analyses are shown as black boxes and the position of
the PCR primers (c and d) used to monitor the transmission of the ZAP-70 Y315F mutation shown as triangles. (E) Southern blot analysis of recom-
binant ES clones before deletion of the neor gene. DNA from parental E14 and from clone 315. B6 that gave germline transmission were digested
with Xba I and hybridized with the 3  probe shown in D. (F) DNA-PCR analysis of wild-type (w/w), heterozygous (w/m), and homozygous (m/m)
littermates using the pair of primers shown in D. The single loxP site left after deletion of the neor gene resulted in an amplified PCR product 140-bp
longer than the one amplified from the wild-type allele.495 Magnan et al.
Y292F and ZAP-70 Y315F thymocytes, a few DP cells ad-
ventitiously expressing Syk at high levels may have been
specifically selected to give rise to populations of SP cells
with unusually high levels of Syk. To compare at the single
cell level the levels of Syk in wild-type and ZAP-70 mu-
tant thymi, thymocytes were permeabilized, stained intra-
cellularly with an anti-Syk antibody, and analyzed by flow
cytometry (31). This analysis showed that both ZAP-70
mutant thymi contained levels of Syk that were identical to
wild-type thymi, and similarly higher in the DN popula-
tion, decreased in the DP population, and low in SP cells
(data not shown). Therefore, in contrast to the compensa-
tory mechanisms that have been previously documented in
some Src family kinase deficiencies (34), the pattern of Syk
expression during T cell development is similar in wild-
type and in the ZAP-70 Y292F and Y315F mutants.
Phosphorylation of Zap-70 and of CD3-  in Thymocytes and
Peripheral T Cells of ZAP-70 Y292F and ZAP-70 Y315F
Mice. We analyzed next the TCR-dependent phosphory-
lation of ZAP-70 Y292F and ZAP-70 Y315F molecules in
both thymocytes and lymph node T cells. As shown in Fig.
2 A, mutation of Y315 markedly impaired the ability of
ZAP-70 to become tyrosine phosphorylated after TCR
stimulation, a finding in agreement with previous observa-
tions made in DT-40 cells (11). Despite the fact that Y292
constitutes a primary in vivo/in vitro tyrosine phosphoryla-
tion site (5), ZAP-70 Y292F molecules showed levels of
induced tyrosine phosphorylation that were equal (thy-
mocytes) or even greater (lymph node T cells) than wild-
type ZAP-70 molecules (Fig. 2 A). The difference noted
between thymocytes and lymph node T cells suggests that
ZAP-70 tyrosine phosphorylation might be regulated in
part via distinct mechanisms in immature and mature T
cells. Reprobing the blot with an antibody against ZAP-70
showed that both ZAP-70 mutant proteins and wild-type
ZAP-70 were expressed at similar levels (Fig. 2 A, middle
panels). Therefore, the differences in inducible tyrosine
phosphorylation documented in Fig. 2 A cannot be as-
cribed to differences in the levels of ZAP-70 expression.
After TCR stimulation, the levels of CD3-  tyrosine
phosphorylation were also affected by the presence of the
ZAP-70 mutants. Higher amounts of 21- and 23-kD ty-
rosine phosphorylated forms of CD3-  (p21 and p23) co-
precipitated with ZAP-70 Y292F than with wild-type
ZAP-70 molecules (Fig. 2 A). Conversely, compared with
wild-type ZAP-70 immunoprecipitates, less p21 and p23
Figure 2. Tyrosine phosphorylation of CD3- , ZAP-70, Cbl, Vav1,
LAT, SLP-76, and PLC -1 in ZAP-70 Y292F and ZAP-70 Y315F mice.
(A) Phosphorylation of ZAP-70 and CD3-  in thymocytes and lymph
node T cells in response to TCR cross-linking. Thymocytes (left) or
lymph node cells (right) were isolated from wild-type (wt), ZAP-70
Y292F (292F), and ZAP-70 Y315F (315F) mice expressing the P14 TCR
transgene. Cells were left unstimulated ( ) or stimulated by CD3 cross-
linking ( ), lysed, and immunoprecipitated with an anti–ZAP-70 an-
tiserum. Samples were then subjected to immunoblotting with
an anti-phosphotyrosine antibody (upper and lower panels). The
amount of immunoprecipitated ZAP-70 was verified by stripping the
membranes and reprobing them with an anti-ZAP-70 monoclonal anti-
body (middle panels). (B) Effect of ZAP-70 Y292F (292F) and ZAP-70
Y315F (315F) on inducible tyrosine phosphorylation. Thymocytes and
lymph node cells from wild-type (wt), 292F and 315F mice expressing
the P14 TCR transgene, were isolated and treated as described in A.
Postnuclear lysates were separated by SDS-PAGE and analyzed by West-
ern blot analysis with the antiphosphotyrosine antibody 4G10. The mo-
lecular weight markers (in thousands) are noted to the left of the blot. (C)
Phosphorylation of SLP-76, LAT, Vav1, Cbl, and PLC -1 in thymocytes
and lymph node T cells in response to TCR cross-linking. Cell lysates were
immunoprecipitated with antisera specific for the proteins specified in the left
margin and each sample analyzed by antiphosphotyrosine immunoblotting.
The blots were subsequently stripped and reprobed with the antibodies used
in the immunoprecipitation to control for protein level. The molecular spe-
cies that are detected are noted to the left of the blots.496 Mice with Mutations in the Interdomain B of ZAP-70
CD3-  forms were bound to the ZAP-70 Y315F mole-
cules. This reduction was not due to an indirect effect of
the ZAP-70 Y315F mutation on the detergent solubility of
the various CD3-  species, as comparable results were ob-
tained when the levels of TCR-inducible CD3-  phosphor-
ylation were assessed by immunoblotting on whole cell ly-
sate or after immunoprecipitation with an anti-CD3- 
antiserum (data not shown). It should be noted that the p21
CD3-  species, a phosphoisoform that is constitutively
present in wild-type thymocytes and lymph node T cells
(35), is also expressed at significantly lower levels in ZAP-
70 Y315F thymocytes than in wild-type or ZAP-70 Y292F
thymocytes (Fig. 2 A). Considering that ZAP-70 is not re-
sponsible for the phosphorylation of the CD3 ITAMs (see
Introduction), the reduced amount of phospho-  species
unexpectedly observed in resting ZAP-70 Y315F-express-
ing T cells suggests that the Y315F mutation may have a
direct or indirect effect on the ability of the ZAP-70 tan-
dem SH2 domains to bind and protect phosphorylated
CD3-  ITAMs (Discussion).
Phosphorylation of Cbl, Vav1, SLP-76, PLC -1, and LAT
in ZAP-70 Y292F and ZAP-70 Y315F Mutant Mice. Af-
ter TCR triggering, the atypical SH2 domain of Cbl binds
with high-affinity to ZAP-70 via the phosphotyrosine-
containing motif Y292TPEP (14, 15), whereas the tyrosine-
phosphorylated Y315 ESP motif found in ZAP-70 has been
proposed to be a docking site for the SH2 domain of Vav1
(36, 37). Considering that both Cbl and Vav1 constitute
candidate substrates for ZAP-70/Syk PTKs (16, 38), we
asked next whether the TCR-induced Cbl and Vav1 ty-
rosine phosphorylation depends on the presence of the
Y292 and Y315 residues, respectively. After TCR cross-
linking, ZAP-70 Y292F thymocytes and lymph node T
cells exhibited levels of Cbl phosphorylation similar to
those found in wild-type cells, whereas the ZAP-70
Y315F-mutant and wild-type T cells present in lymph
nodes and thymus displayed comparable levels of phos-
phorylated Vav1 species (Fig. 2 C). The latter result is in
line with previous data, obtained in transformed T cell
lines, and showing that the expression of ZAP-70 Y315F
mutant molecules did not affect the extent of CD3-
induced Vav1 phosphorylation (8, 10). Taken together,
our results demonstrate that Y292 and Y315 are dispens-
able for the TCR-induced tyrosine phosphorylation of
Cbl and Vav1, respectively. They further suggest that
other molecules present in the TCR signaling cassette
(e.g., SLP-76 in the case of Vav1, and Nck or LAT in the
case of Cbl; for a review, see reference 39) act as additional
adaptors for Cbl and Vav1.
Considering that the TCR-dependent phosphorylation
of CD3-  and ZAP-70 is enhanced by the Y292F mutation
and attenuated by the Y315F mutation, we also examined
whether these differences affect signaling events further
downstream in the T cell activation cascade. Probing post-
nuclear T cell lysates from wild-type and ZAP-70 mutants
with an antiphosphotyrosine antibody showed an increase
in the inducible tyrosine phosphorylation of several discrete
bands in ZAP-70 Y292F and conversely a reduction in the
antiphosphotyrosine reactivity of the same bands in ZAP-
70 Y315F (Fig. 2 B). A more extensive analysis of the
phosphorylation state of individual proteins was under-
taken. We chose to analyze the phosphorylation levels of
the adaptor protein LAT and SLP-76 since they constitutes
primary substrates of ZAP-70 (for a review, see reference
39). Compared with wild-type ZAP-70 molecules for their
ability to contribute to the TCR-induced phosphorylation
of LAT, and SLP-76, ZAP-70 Y315F mutant molecules
showed comparable activity when analyzed in thymocytes
and similar (SLP-76) or slightly reduced activity (LAT)
when analyzed in the context of lymph node T cells (Fig. 2
C). Therefore, the greatly diminished tyrosine phosphory-
lation of CD3-  and ZAP-70 in ZAP-70 Y315F-express-
ing T cells does not appear to have a commensurate impact
on LAT or SLP-76 phosphorylation. In contrast, when an-
alyzed in lymph node T cells and compared with wild-type
ZAP-70, expression of ZAP-70 Y292F molecules mark-
edly increased the TCR-induced tyrosine phosphorylation
of LAT and SLP-76 (Fig. 2 C). In thymocytes, the ZAP-70
Y292F mutant significantly increased only the inducible ty-
rosine phosphorylation of LAT. After anti-CD3  antibody
stimulation, the wild-type and mutant T cells displayed al-
most the same degree of tyrosine phosphorylation on phos-
pholipase C (PLC) -1 (Fig. 2 C). On the basis of these re-
sults, we conclude that the ZAP-70 Y292F and ZAP-70
Y315F mutations selectively affected the TCR induced
phosphorylation of a subset of signal transducers.
TCR-   Selection in ZAP-70 Y292F and ZAP-70
Y315F Mutant Thymocytes. Because of the epigenetic
mechanisms that shape the repertoire of TCRs expressed
on mature T cells, selection of TCRs with lower or higher
affinity for self-MHC might have compensated for the
ZAP-70 Y292F and ZAP-70 Y315F mutations, respec-
tively. When tested in mice in which TCR variability is
neutralized by coexpressing a transgenic TCR originally
calibrated in the context of a normal TCR signaling cas-
sette, the effects of the ZAP-70 Y292F or ZAP-70 Y315F
mutations may become more salient. Therefore, each
ZAP-70 mutation was introduced into two different TCR
transgenic lines. One, denoted H-Y, expresses a TCR spe-
cific for the male H-Y antigen (24, 25), and the other one,
denoted P14, a TCR specific for a peptide derived from
the lymphocytic choriomeningitis virus glycoprotein (23).
In both instances, the cognate peptide is presented in the
context of H-2Db molecules.
As shown in Fig. 3, the analysis of ZAP-70 mutant mice
carrying the P14 TCR transgene did not reveal any major
effect of either mutation on the generation of CD8 /
V 2high thymocytes and lymph node T cells. When com-
pared with the P14 TCR, the H-Y TCR appears to bind
with a lower affinity to its selecting ligand (40), and thus
might constitute a more sensitive reporter of the signaling
capacity of the ZAP-70 Y292F and Y315F molecules. In
wild-type female thymi, the interaction of the H-Y TCR
with unknown self ligand(s) results in the selection of
CD8  SP cells that express high levels of the transgenic
TCR (detected by the specific antibody T3.70). As shown497 Magnan et al.
in Fig. 4, the Y292F mutation did not detectably affect
positive selection as documented by the number and per-
centage of CD8 /T3.70high cells found in the thymus and
the lymph nodes. This suggests either that the Y292F mu-
tation has no enhancing effect on positive selection, or that
in the H-Y TCR system, this developmental transition is
already operating at a maximum rate. In contrast, the per-
centage and total number of CD8 /T3.70high cells found in
the thymus and the lymph nodes of ZAP-70 Y315F mice
showed a consistent reduction (two to threefold range)
when compared with wild-type and ZAP-Y292F mice
(Fig. 4).
Due to a premature expression of the H-Y TCR trans-
gene, the T cells that arise in H-Y TCR transgenic male
thymus are negatively selected before or at the transition to
the DP stage (41). This results in the depletion of the DP
and SP populations and in a severely reduced thymic cellu-
larity. This last feature was unchanged after introducing the
H-Y TCR on a ZAP-70 Y292F or ZAP-70 Y315F back-
ground (Fig. 4). However, when compared with H-Y
TCR wild-type thymi, H-Y TCR/ZAP-70 Y315F thymi
showed a novel T3.70high/DP cell population that repre-
sented  30% of the thymocytes. Its appearance does not
result in a concomitant increase in thymic cellularity, or in
the presence of peripheral CD8 /T3.70high cells. There-
fore, negative selection is still taking place in H-Y TCR/
ZAP-70 Y315F mice. However, due to a probable de-
crease in the TCR signaling potential of the ZAP-70
Y315F-expressing T cells, negative selection is in part de-
layed until the DP stage of T cell development. Con-
versely, the enhanced TCR signaling potential thought to
be associated with the presence of ZAP-70 Y292F mole-
cules (see above), should have resulted in a more effective
negative selection. Consistent with this view, the expres-
sion of ZAP-70 Y292F prevented the development of
T3.70 /DP cells (Fig. 4). These cells normally arise in H-Y
TCR transgenic male thymus after the expression of an en-
dogeneous TCR   chain capable of displacing the trans-
genic TCR   chain from the cell surface, and therefore of
protecting them from negative selection. By exacerbating
the efficiency of negative selection at the DN stage, it is
likely that the ZAP-70 Y292F mutation prevented the oc-
currence of endogeneous TCR   gene rearrangements and
thus totally blocked the emergence of T3.70 /DP cells.
CD5, a cell surface molecule expressed on thymocytes
and on most mature T cells, functions as a negative regula-
tor of TCR-mediated signaling (42). Its expression is up-
regulated on DN cells via signaling by the pre-TCR. On
DP cells, intermediate CD5 levels are maintained by low
affinity TCR–MHC interactions (43, 44). Wild-type,
ZAP-70 Y292F, and ZAP-70 Y315F DN and DP cells iso-
lated from P14 or female H-Y TCR transgenic thymi ex-
pressed similar levels of CD5 (Fig. 5, and data not shown),
an observation consistent with the view that any effect asso-
ciated with the ZAP-70 mutations should be detectable
only during or after TCR    selection (see above). Inter-
estingly, the levels of CD5 expression reached on SP cells
have been shown to be proportional to the TCR signaling
capacity (43). For instance, expression of an    TCR with
a lowered signaling potential is generally accompanied by
the selection of SP cells expressing lower levels of the CD5
negative regulator (43). In this context, SP thymocytes
from both H-Y TCR/ZAP-70 Y315F and P14 TCR/
ZAP-70 Y315F mice were found to express lower surface
levels of CD5 than SP thymocytes from the same TCR
transgenics bred on a wild-type or a ZAP-70 Y292F back-
Figure 3. T cell development
in ZAP-70 Y292F and ZAP-70
Y315F mice expressing the P14
transgenic TCR. Thymocytes
and total lymph node cells from
wild-type (WT), ZAP-70
Y292F, and ZAP-70 Y315F
mice expressing the P14 TCR
transgene were analyzed by
three-color flow cytometry for
expression of CD4, CD8, and
V 2. For two-color plots, the
percentage of cells found in each
quadrant is indicated. For single-
color profiles of total thymocytes
the filled histograms depict the
levels of V 2 staining observed
on total thymocytes. Also shown
is the percentage of V 2-positive
cells scoring within either the
TCR intermediate plus high
windows or in the TCR high
window alone. The slight in-
crease in the percentage of
V 2high cells noted in ZAP-70
Y292F thymocytes was not
found significant when data from
a larger number of mutant mice
were analyzed.498 Mice with Mutations in the Interdomain B of ZAP-70
ground (Fig. 5). Moreover, this relative difference in CD5
surface expression was maintained on lymph node T cells
(Fig. 5). Therefore, this observation further suggests that
TCRs functioning in the context of ZAP-70 Y315F mu-
tant molecules have a lowered signaling potential, and that
the corresponding T cells rely on CD5-based compensatory
adjustments to reach the signaling threshold required for
positive selection, in that only those cells with a sufficiently
low level of CD5 expression could be positively selected.
Effects of the ZAP-70 Mutations on TCR/CD3 Downregu-
lation and Expression of Surface Activation Markers. The ob-
servation that both engineered ZAP-70 mutations do not
detectably affect the development of P14 TCR transgenic
cells offers the possibility to address ex vivo the functional
properties of mature T cells expressing ZAP-70 Y292F or
ZAP-70 Y315F mutant kinases. If we except the differ-
ence previously noted for CD5, all the CD8  cells found
in the periphery of ZAP-70 mutant mice express the same
surface phenotype and qualify as naive resting T cells, in
that they express a CD25  CD44low, CD62Lhigh, and
CD69  phenotype (data not shown). CD8  lymph node
T cells were purified from wild-type, ZAP-70 Y292F, and
ZAP-70 Y315F mice expressing the P14 TCR transgene
and cultured with RMA-S cells pulsed with graded doses
of peptides p33 or AV. p33 constitutes a strong agonist for
the P14 TCR (45), whereas AV, an adenovirus peptide
known to efficiently bind to H-2Db, was used as a nega-
tive control (46). After 15 h of culture, cells were har-
vested and stained for V 2, CD3 , CD25, or CD69 ex-
pression. Fig. 6 shows the expression of these various
markers on gated CD8  T cells. Upon challenge with the
agonist peptide, T cells from ZAP-70 Y292F and ZAP-70
Y315 mice were as efficient as their wild-type counterpart
at downregulating their TCR/CD3 complexes and at up-
Figure 4. T cell development in ZAP-70
Y292F and ZAP-70 Y315F mice expressing
the H-Y transgenic TCR. Thymocytes and
total lymph node cells from wild-type
(WT), ZAP-70 Y292F, and ZAP-70 Y315F
female or male mice expressing the H-Y
TCR transgene were analyzed by three-
color flow cytometry for expression of
CD4, CD8, and of the transgenic TCR  
chain used by the H-Y TCR (T3.70). The
percentage of cells found in each window is
indicated. In the two-color plots shown in
the right-hand part of the upper set, the val-
ues in italic correspond to the mean CD8
fluorescence intensity found on T3.70 /
CD8  thymocytes. Numbers above the
plots indicate the total number of thy-
mocytes   SD. These data are representa-
tive of six experiments.499 Magnan et al.
regulating the CD25 and CD69 molecules. When TCR
expression was measured at earlier time points, the degree
of TCR downmodulation was lower on ZAP-70 Y292F
T cells, suggesting a slower rate of antigen-induced TCR
internalization on these cells as compared with wild-type
and ZAP-70 Y315F T cells (Fig. 6 D). No TCR/CD3
downregulation and no CD25 or CD69 upregulation
were seen on V 2 /CD4  T cells or with the negative
control peptide AV (data not shown).
Effects of the ZAP-70 Mutation on Proliferation and Cytokine
Production. When challenged with the p33 peptide,
CD8  lymph node T cells purified from ZAP-70 mutant
Figure 5. CD5 expression on DP thymocytes,
SP CD8  thymocytes, and CD8  peripheral T
cells from P14 and female H-Y transgenic mice
expressing mutated ZAP-70 molecules. Compari-
son of CD5 levels on DP thymocytes (A and B),
CD8  SP thymocytes (C and D), and CD8 
lymph node cells (E and F) from H-Y and P14
transgenic mice expressing wild-type (dotted line),
ZAP-70 Y292F (thin line), or ZAP-70 Y315F
(bold line) molecules. Cells were analyzed by four-
color cytometry for expression of CD4, CD8,
CD5, and T3.70 (H-Y mice) or V 2 (P14 mice).
Single-color histograms represent CD5 staining on
transgenic, clonotype positive cells. Numbers at
the top right part of each panel indicate the mean
CD5 fluorescence intensity found on clonotype-
positive cells expressing wild-type (1), ZAP-70
Y292F (2), or ZAP-70 Y315F (3) molecules.
These data are representative of four experiments.
Figure 6. TCR downregulation and expression of
CD25 and CD69 on CD8  T cells isolated from P14
mice expressing wild-type ZAP-70 (wt), ZAP-70
Y292F, and ZAP-70 Y315F molecules and after stimu-
lation with the p33 agonist peptide. RMA-S cells
(2.5   105) were prepulsed with graded concentrations of
antigenic peptide and cultured with T cells (1.5   106)
purified from P14 transgenic mice expressing wild-type
or mutant ZAP-70 molecules. After 12–15 h, levels of
TCR/CD3 complexes, CD25 and CD69 were deter-
mined by flow cytometry on gated CD8  T cells. One
representative experiment of two is shown. (A) TCR
downregulation. Data are given as percent mean fluo-
rescence intensity of T cells cultivated for 12–15 h with
RMA-S cells pulsed with an irrelevant H-2 Db–bind-
ing peptide. Similar values were obtained by using ei-
ther anti-V 2 or anti-CD3-  antibodies. (B and C)
CD69 and CD25 upregulation. Data show the percent
of CD69  (B) or CD25  (C) cells found among CD8 
T cells. (D) Downmodulation of surface TCR and up-
regulation of CD69 on lymph node T cells isolated
from the specified mice after 2.5 h of stimulation with
RMA-S cells that were prepulsed with an irrelevant
peptide (top), or with the p33 peptide (bottom). Gated
CD8  cells were analyzed for expression of V 2 and
CD69 after 2.5 h of culture. Numbers in each panel in-
dicate the percentage of cells and their TCR mean
fluorescence intensity value. These data are representa-
tive of four experiments.500 Mice with Mutations in the Interdomain B of ZAP-70
mice expressing the P14 TCR transgene showed prolifera-
tive dose-response curves almost superimposable to those
obtained with wild-type P14 T cells (Fig. 7). However,
when challenged with a subnanomolar (10 11 M) concen-
tration of p33 peptide, ZAP-70 Y292F-expressing cells
consistently proliferated more than wild-type P14 T cells,
whereas no proliferation was observed for ZAP-70 Y315F–
expressing cells. To follow the kinetics of division of indi-
vidual P14  T cells expressing wild-type or mutant ZAP-
70 molecules in response to suboptimal concentrations
(10 8 to 10 9 M) of p33 agonist peptide, we used the fluo-
rescent dye carboxyfluorescein succinimidyl ester (CFSE).
CFSE segregates equally between daughter cells upon cell
division, resulting in the sequential halving of cellular fluo-
rescence intensity within each successive generation (47).
Analysis of the flow cytometry profiles measured at time
points extending up to 72 h, and calculation of the corre-
sponding division index (48) did not reveal any differences
between P14  T cells expressing wild-type and ZAP-70
mutant molecules. When lymph node T cells from ZAP-
Y292F/P14, ZAP-Y315F/P14, and wild-type P14 mice
were stimulated in vitro with suboptimal dose of p33 ago-
nist peptide or of the partial agonist peptides M3V and
L3V, the cytotoxic effectors generated after a 3 d-culture
were all capable of efficiently lysing RMA-S target cells
pulsed with suboptimal concentration of p33 (10 9 M),
M3V(10 7 M), or L3V(10 6 M) peptides (data not shown).
During these comparative analyses, the only robust differ-
ence was found at the level of IL-2 production. Whereas
P14 T cells expressing ZAP-70 wild-type and ZAP-70
Y315F molecules produced equivalent levels of IL-2 in re-
sponse to graded concentrations of p33 peptide, P14 T cells
expressing ZAP-70 Y292F molecules consistently yielded
two to threefold more IL-2 (Fig. 7 B). This enhanced IL-2
production may result from a greater response per cell or
from a greater number of responding cells, with a produc-
tion per cell remaining relatively constant. To settle this is-
sue, we analyzed cytokine production at the single cell
level, using a flow cytometric assay for intracellular cyto-
kine levels. IL-2 and IFN-  production tests were selected
since P14  T cells stimulated with suboptimal dose of ago-
nist peptide and without addition of exogeneous cytokines
are capable of producing readily detectable levels of these
two cytokines (49). As shown in Fig. 8 A, naive CD8  T
cells purified from mice expressing wild-type and mutant
ZAP-70 molecules expressed neither IL-2 nor IFN- . Af-
ter in vitro stimulation with the p33 peptide, the number
of IL-2–producing T cells reached a maximum within 20 h
and rapidly declined to baseline levels at 40 h, whereas the
number of IFN- –producing T cells found in each culture
reached a plateau between 20 and 40 h of culture, and de-
clined thereafter. At 20 h, the majority of responding cells
make either IFN-  or IL-2, and only a minority of them
produced both cytokines. Therefore, expression of ZAP-
70 mutants molecules had no marked effect on the kinetics
of cytokine production, and resulted in a rather normal
range of IL-2 and IFN-  staining intensities. However, as
shown on Fig. 8 B, in the presence of the ZAP-70 Y292F
molecules, the percentages of IL-2- or IFN- -producing
cells were consistently greater than those reached in cell
populations expressing ZAP-70 wild-type or ZAP-70
Y315F molecules. Therefore, this difference is consistent
with that already documented when IL-2 production was
measured at the cell population level (Fig. 7 B). Impor-
tantly, these results indicate that the enhanced TCR signal-
ing potential resulting from the ZAP-70 Y292F mutation
does not lead to a greater range of IL-2 (or IFN- ) produc-
tion per cell, but rather translates into a greater number of
responding T cells. They also demonstrate that the minute
amounts of ZAP-70 phosphorylation that are induced by
TCR stimulation in ZAP-70 Y315F T cells (Fig. 2 A) are
nonetheless sufficient to activate the pathways leading to
cytokine production and cell cycle entry.
Discussion
The present in vivo and ex vivo analyses extend previous
studies based on transformed cell lines, and show that Y292
plays a role in the attenuation of TCR signaling, whereas
Y315 enhances ZAP-70 function. The regulatory proper-
Figure 7. Proliferative responses and IL-2 secretion. H-2 Db-positive
spleen cells (5   105) isolated from CD3 -deficient mice were pulsed for
2 h with graded concentrations of p33 agonist peptide and subsequently
cultured with purified CD8  T cells isolated from P14 mice expressing
wild-type ZAP-70 (wt), ZAP-70 Y292F, or ZAP-70 Y315F molecules.
(A) After 40 h, T cell proliferation was assessed by pulsing cultures with
[3H]TdR for 8 h. (B) After 40 h, supernatants were assayed for IL-2 con-
tents. Data correspond to the mean response of independent cultures es-
tablished from two mice of each genotype. One representative experi-
ment of three is shown.501 Magnan et al.
ties of phospho-Tyr 315 have been attributed to its ability
to recruit Vav1 (11). In Vav1-deficient mice, both the DN
to DP and DP to SP transitions are partially blocked, and
the total number of mature CD4  and CD8  T cells re-
duced twofold when compared with wild-type mice. Anal-
ysis of Vav1-deficient T cells, further showed that they ex-
press normal levels of TCR and CD5, and that after TCR
stimulation, Vav1 has an important role in cell cycle pro-
gression and IL-2 production (50). We showed that when
analyzed in the context of the “sensitized” genetic back-
ground provided by the H-Y TCR transgenic line, the
ZAP-70 Y315 mutation reduced the rate of positive selec-
tion and delayed the occurrence of negative selection up to
the DP stage. However, P14  lymph node T cells express-
ing ZAP-70 Y315F were as efficient as wild-type P14  T
cells when tested for their ability to proliferate and secrete
IFN-  and IL-2. Although, the decreased levels of CD5
found on ZAP-70 Y315F mature T cells precludes a fair
comparison of their properties with those found in Vav1-
deficient mice, the effects of the ZAP-70 Y315F mutation
appear however milder than those resulting from the lack
of Vav1. Along this line, it should be noted that in marked
contrast to Vav1 /  thymocytes (51), ZAP-70 Y315F thy-
mocytes display TCR-induced Ca2  responses similar to
those found in wild-type thymocytes (data not shown).
That Vav1 ablation and Y315F are not equivalent is also
indicated by the fact that some very early events induced
by TCR engagement, in particular the tyrosine phosphory-
lation of the CD3- , chain, are unaffected by the absence
of Vav1 but clearly defective in ZAP-70 Y315F-expressing
T cells (see below).
The asymetrical contributions of residue Y315 of ZAP-
70 and of Vav1 to both T cell development and function
suggest that among the multiple phosphotyrosine-based
motifs that connect Vav1 to the TCR transduction cassette
(for a review, see reference 39), the one found in ZAP-70
might not play a major role. Consistent with the existence
of additional Vav1-entry sites, ZAP-70 Y315F-expressing
T cells retained the ability to phosphorylate Vav1 upon
TCR triggering. Whether the ablation of the Vav1 dock-
ing site(s) found in SLP-76 more appropriately recapitulates
the phenotype observed in Vav1-deficient mice remains to
be tested. Considering that the existence of a direct interac-
tion between the phosphorylated-Y315ESP motif and Vav1
has not yet been validated on a genetic basis (i.e., by estab-
lishment of interaction suppressors or enhancers), it remains
formally possible that the effects noted in ZAP-70 Y315F
mice do not directly result from a lack of interaction be-
tween Vav1 and ZAP-70. For instance, the ZAP-70
Y315F mutation reduced both the constitutive phosphory-
lation of CD3-  and the inducible phosphorylation of
CD3-  and ZAP-70 (Fig. 2 A), two features that are nota-
bly absent in Vav1-deficiency (52, 53). When tested in
Syk-deficient DT-40 chicken cells, mutation of residue
Figure 8. Cytokine production
analyzed at the single cell level.
CD8  cells purified from P14 mice
expressing wild-type (wt), ZAP-70
Y292F, or ZAP-70 Y315F mole-
cules were cultured in the presence
of CD3 -deficient spleen cells and of
suboptimal concentration (10 8 M)
of the p33 agonist peptide. At the
specified time, both IFN-  and IL-2
levels were quantified by intracellu-
lar staining. (A) IFN-  versus IL-2
two-color plots after gating on
CD8  cells. Before intracellular
staining cells were incubated for 4 h
in the presence of monensin. (B)
The percentage of CD8  T cells ex-
pressing IFN-  or IL-2 is shown for
various culture time points. Data
correspond to the mean response
(  SD) of independent cultures es-
tablished from two mice of each ge-
notype. One representative experi-
ment of four is shown.502 Mice with Mutations in the Interdomain B of ZAP-70
Y315 similarly reduced the antigen receptor-inducible
ZAP-70 tyrosine phosphorylation, without exerting any
detectable effect on the kinase activity of ZAP-70 and on
its capacity to bind to phosphorylated ITAMs (11). We re-
cently confirmed that mutation of residue Y315 does not
affect the intrinsic kinase activity of ZAP-70. However, in
contrast to the results obtained in DT-40 cells, using cell
lysates prepared from thymoctes and lymph node T cells,
we found that the ZAP-70 Y315F molecules bind to bi-
phosphorylated ITAMs with an affinity that is two to
threefold lower than that of wild-type ZAP-70 molecules
(data not shown). This difference in affinity may suffice to
reduce the ability of the tandem SH2 domains to protect
phosphorylated ITAMs from the constitutive action of ty-
rosine phosphatases, and may account for the markedly re-
duced levels of the CD3-  p21 and p23 phosphoisoforms,
and for the reduced phosphorylation of ZAP-70 and LAT
found in ZAP-70 Y315-expressing T cells. Importantly, a
Tyr to Phe substitution at either position 292 or 319 of in-
terdomain B did not produce a similar destabilizing effect
(Fig. 2 A, and data not shown). Therefore, once phos-
phorylated, Y315 may specifically contribute, in a direct
or indirect mode, to enhance the binding of ZAP-70 to
phosphorylated ITAMs. Consistent with this possibility,
comparison of Syk and of SykB, a naturally occurring iso-
form of Syk that lacks 23 amino acids in interdomain B, al-
ready showed that interdomain B can regulate the ability of
Syk to bind ITAMs (54). Regardless of the exact mecha-
nism through which Y315 modulates the binding ability of
the ZAP-70 SH2 domains, our data suggest that interdo-
main B of ZAP-70 also takes part in the control of the dy-
namic interactions that exist between ITAMs and ZAP-70
(20, 55, 56). Finally, the observation that the defective
phosphorylation of ITAMs and ZAP-70 in Y315F mutant
mice correlates with a decreased phosphorylation of LAT
but not Vav1 (Fig. 2), further suggests that the former but
not the latter is a direct substrate of ZAP-70.
A wealth of biochemical and structural data suggests that
the negative regulatory properties of residue Y292 results
from its ability to recruit the Cbl and Cbl-b adaptors (14,
57, 58). Cbl and Cbl-b share a high degree of homology
over their NH2-terminus SH2 and RING finger domains,
but diverge almost immediately after the RING finger do-
main. The RING finger found in Cbl can recruit E2 ubiq-
uitin-conjugating enzymes and function as an E3 ubiquitin
ligase (for a review, see reference 15). Compared with
wild-type, in both Cbl-deficient and ZAP-70 Y292F thy-
mocytes, CD3- , ZAP-70, and LAT molecules become
more tyrosine phosphorylated after TCR cross-linking
(59–61). In contrast, the loss of Cbl-b has no notable effect
on the inducible tyrosine phosphorylation of CD3- , ZAP-
70 and LAT, and Cbl-b /  T cells display a distinctive hy-
perproduction of IL-2 but not of IFN-  that distinguish
them from ZAP-70 Y292F T cells (57, 62). Therefore, the
partially overlapping phenotype found in thymocytes and
T cells from Cbl-deficient and ZAP-70 Y292F mice is
consistent with the assumption that ZAP-70 and Cbl inter-
act via the Tyr 292-containing motif. After TCR cross-
linking, ZAP-70 Y292F-expressing T cells retained, how-
ever, their ability to increase the tyrosine phosphorylation
of Cbl. Although these results indicate that multiple Cbl
docking sites exist within the TCR signaling cassette, it
should be emphasized that each of them may not be func-
tionally equivalent. For instance, the rigid arrangement ex-
isting between the SH2 and RING E3 domains of Cbl (15)
may result in a highly selective ubiquitin transfer, and a dis-
tinct spectrum of lysine residues is likely to be targeted ac-
cording to the docking site used by the Cbl SH2 domain.
The exact biochemical mechanisms by which the ZAP-70
Y292F mutation enhances TCR signaling remain to be de-
termined. Once bound to the Y292-based motif, Cbl may
prevent the docking of a positive regulator to ZAP-70 (for
a review, see reference 63). Alternatively, by being brought
in contiguity with the proximal components of the TCR
transduction cassette, the COOH terminus of Cbl may act
as a scaffold to which negative regulators bind. However,
based both on the presence of a RING E3 domain adjacent
to the Cbl SH2 domain, and on the fact that the CD3 sub-
units undergo activation-dependent multiubiquitination
(64, 65), it is tempting to speculate that the Y292/Cbl in-
teraction enhances the ubiquitin-dependent downregula-
tion of the activated TCR, as previously documented for
receptors for the epidermal growth factor and the colony-
stimulating factor 1 (for a review, see reference 66). Con-
sistent with this hypothesis, Cbl deficiency resulted in
slightly higher steady state levels of TCR–CD3 complexes
(58, 59). Although we have not been able to detect a simi-
lar increase in the amount of TCR expressed at the cell
surface, we observed a delayed downmodulation of the
TCR after antigen stimulation (Fig. 6 D). This last obser-
vation is consistent with the fact that the internalization
motifs present in CD3-  and CD3-  (67) play no major
role in antigen-induced TCR downregulation (68). How-
ever, it remains to establish whether the slower antigen-
induced TCR downregulation rate noted in ZAP-70
Y292F-expressing T cells directly results from attenuated
TCR ubiquitination, and permits a larger fraction of T cells
to reach the elicitation threshold required for the produc-
tion of IL-2 and IFN-  (Figs. 6 and 8). Finally, it is inter-
esting to note that both the ZAP-70 mutations we have
engineered and the deficiencies in Cbl or Cbl-b modify
rather than ablate the transducing cassette operated by the
TCR. In Caenorhabiditis elegans, mutations of the Cbl ho-
mologue Sli-1 alone does not produce any observable phe-
notypic changes unless bred on sensitized genetic back-
grounds expressing weakly active alleles of an epidermal
growth factor receptor homologue (69). Similarly, when
introduced into a sensitized Vav1-deficient background,
the Cbl-b null mutation was found capable of relieving the
signaling defects found in Vav1 /  T cells (70). Based on
the latter example, it is expected that further crossing of the
ZAP-70 Y292F and Y315F mutations onto mouse strains
expressing weak alleles of the various components of the
TCR transduction cassette will exacerbate their modifier
properties and thus contribute to pinpoint the mechanisms
by which these two residues exert their regulatory effects.503 Magnan et al.
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